Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24302602 | 0.82 | TAAR1 (0.43) | ADRB1ADRB3CES2CES1 | |
| SCHEMBL26326772 | 0.81 | CYP2D6 (0.49) | CYP2D6HIF1AKDM4EADRB2ADRB1 | |
| SCHEMBL24370608 | 0.77 | CES2 (0.42) | KDM4EADRB2CES2CES1 | |
| SCHEMBL26326775 | 0.77 | CYP2D6 (0.43) | CYP2D6HIF1AKDM4EADRB2ADRB1 | |
| SCHEMBL28410212 | 0.74 | CES2 (0.42) | CYP2D6ADRB1ADRB3CES2CES1 | |
| SCHEMBL26326758 | 0.73 | ADRB1 (0.46) | CYP2D6HIF1AKDM4EADRB2ADRB1 | |
| SCHEMBL30606520 | 0.73 | CSNK1E (0.39) | CES2CES1MEN1KMT2A | |
| SCHEMBL12312535 | 0.73 | CYP2D6 (0.54) | CYP2D6HIF1AKDM4EADRB2ADRB1 | |
| SCHEMBL12312536 | 0.73 | CYP2D6 (0.54) | CYP2D6HIF1AKDM4EADRB2ADRB1 | |
| SCHEMBL10535014 | 0.73 | CYP2D6 (0.54) | CYP2D6HIF1AKDM4EADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | RIPK1, RIPK3, RIPK4 | CYP2D6 2658/4885HIF1A 3603/4885KDM4E 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.